Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Longwood Fund

Longwood Fund

Longwood Founders Fund is a venture fund that finances science-based companies that develop solutions for medical problems.

Longwood Fund was founded in 2010 by Christoph Westphal, Michelle Dipp and Richard Aldrich. Longwood Fund Management, LLC operates as a venture capital firm. The company invests in healthcare and life science sectors with a focus on biotechnology and therapeutics. Longwood Fund Management serves its clients in the United States.

Longwood's mission is to identify technologies and fund companies that make a difference in the lives of patients, and also create significant value for investors. Longwood's stated goal is to launch and building healthcare companies and provide operational leadership and strategic guidance.

Founders

Christoph Westphal MD, PhD, has served as co-founder, CEO, and lead investor of six companies (including Alnylam, Acceleron, Sirtris, and Momenta) that have completed IPOs, yielding an aggregate, sustained, value of $16 billion. Rich Aldrich was a co-founder of Vertex Pharmaceuticals, which currently has a market capitalisation of $60 billion.

Investments

Longwood Founders Fund invests during early stage and late stage venture as well as dealing with Private Equity. Longwood Founders Fund has raised a total of $85 million across 4 funds, their latest being Longwood Fund V. Investments include Recros Medica, Bicycle Therapeutics and Channel Medsystems with exits including Flex Pharma, Verastem Oncology and PTC Therapeutics.

Timeline

Invested in

Patents

Funding Rounds Participated In

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
FinSMEs
August 19, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Amirah Al Idrus
March 16, 2021
FierceBiotech
A pair of former bluebird bio executives are reuniting at Be Biopharma, a biotech developing B-cell therapies that launched last October. Joanne Smith-Farrell, Ph.D., is Be Bio's new CEO, while Rick Morgan, Ph.D., takes the post of chief scientific officer.
November 10, 2020
BioSpace
TScan Therapeutics Announces Partnership with QIAGEN to Develop T Cell-Based Laboratory Test for Comprehensive COVID-19 Immune Response - read this article along with other careers information, tips and advice on BioSpace

References

Golden logo
By using this site, you agree to our Terms & Conditions.